Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer.
Gray, Steven G
Pidgeon, Graham P
O'Byrne, Kenneth J
AffiliationDepartment of Clinical Medicine, Translational Cancer Research Group, Institute, of Molecular Medicine, Trinity Centre for Health Sciences, St. James' Hospital,, Dublin, Ireland.
Carcinoma, Non-Small-Cell Lung/*enzymology/*genetics
Carcinoma, Squamous Cell/enzymology/genetics
Cytochrome P-450 Enzyme System/*metabolism
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
MetadataShow full item record
CitationCancer. 2011 Nov 15;117(22):5121-32. doi: 10.1002/cncr.26168. Epub 2011 Apr 26.
AbstractBACKGROUND: Prostacyclin synthase (PGIS) metabolizes prostaglandin H(2), into prostacyclin. This study aimed to determine the expression profile of PGIS in nonsmall cell lung cancer (NSCLC) and examine potential mechanisms involved in PGIS regulation. METHODS: PGIS expression was examined in human NSCLC and matched controls by reverse transcriptase polymerase chain reaction (RT-PCR), Western analysis, and immunohistochemistry. A 204-patient NSCLC tissue microarray was stained for PGIS and cyclooxygenase 2 (COX2) expression. Staining intensity was correlated with clinical parameters. Epigenetic mechanisms underpinning PGIS promoter expression were examined using RT-PCR, methylation-specific PCR, and chromatin immunoprecipitation analysis. RESULTS: PGIS expression was reduced/absent in human NSCLC protein samples (P < .0001), but not mRNA relative to matched controls. PGIS tissue expression was higher in squamous cell carcinoma (P = .004) and in male patients (P < .05). No significant correlation of PGIS or COX2 expression with overall patient survival was observed, although COX2 was prognostic for short-term (2-year) survival (P < .001). PGIS mRNA expression was regulated by DNA CpG methylation and histone acetylation in NSCLC cell lines, with chromatin remodeling taking place directly at the PGIS gene. PGIS mRNA expression was increased by both demethylation agents and histone deacetylase inhibitors. Protein levels were unaffected by demethylation agents, whereas PGIS protein stability was negatively affected by histone deacetylase inhibitors. CONCLUSIONS: PGIS protein expression is reduced in NSCLC, and does not correlate with overall patient survival. PGIS expression is regulated through epigenetic mechanisms. Differences in expression patterns between mRNA and protein levels suggest that PGIS expression and protein stability are regulated post-translationally. PGIS protein stability may have an important therapeutic role in NSCLC.
- Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines.
- Authors: Stearman RS, Grady MC, Nana-Sinkam P, Varella-Garcia M, Geraci MW
- Issue date: 2007 Mar
- Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
- Authors: Metzger R, Vallbohmer D, Müller-Tidow C, Higashi H, Bollschweiler E, Warnecke-Eberz U, Brabender J, Baldus SE, Xi H, Berdel WE, Serve H, Hoelscher AH, Schneider PM
- Issue date: 2009 Apr
- Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
- Authors: Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J
- Issue date: 2010 Mar 1
- Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
- Authors: Zhong S, Fields CR, Su N, Pan YX, Robertson KD
- Issue date: 2007 Apr 19
- Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
- Authors: Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H
- Issue date: 2002 Apr 15